Log In Sign up
The largest database of trusted experimental protocols

Epacadostat

Manufactured by Targetmol
Visit Supplier

Epacadostat is a lab equipment product manufactured by Targetmol. It is an indoleamine 2,3-dioxygenase (IDO) inhibitor used in research and development applications.

Automatically generated - may contain errors

Lab products found in correlation

Anti pd 1 clone rmp1 14, by BioXCell (1 mentions) Recombinant human ifn γ, by BioLegend (1 mentions) Ch223191, by Merck Group (1 mentions) Mycoalert, by Lonza (1 mentions)

2 protocols using epacadostat

1

Dual IDO1/TDO2 Inhibitor AT-0174 Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The dual IDO1/TDO2 inhibitor AT-0174, a novel, orally-bioavailable, isoxazolopyridin-3-amine compound, was provided for use by Antido Therapeutics (Melbourne, Australia). AT-0174, a proprietary, novel, small molecule was developed as part of a novel compound chemical synthesis and screening program, from an isoxazolopyridine-based pharmacophore (Patent# US20210145839A1) by Antido Therapeutics (Supplementary Table S1). The compound was stored at − 20 °C and formulated as a solution in 95% water + 5% methylcellulose (0.5%) to provide a fine suspension suitable for oral gavage treatment. The selective IDO1 inhibitor (epacadostat, cat no. T3548) or TDO2 inhibitor (LM10, cat no. T4410) were obtained from Targetmol and stored at − 20 °C. epacadostat and LM10 were also formulated in 95% water + 5% methylcellulose (0.5%) for in vivo oral administration to mice. Antibody against PD-1 (anti-PD-1 clone RMP1-14, cat no. BE0146) was obtained from BioXCell and stored at 4 ˚C. Antibody was administered intraperitoneally every 3 days. Normal saline was used as a control injection.
Wu C., Spector S.A., Theodoropoulos G., Nguyen D.J., Kim E.Y., Garcia A., Savaraj N., Lim D.C., Paul A., Feun L.G., Bickerdike M, & Wangpaichitr M. (2023). Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer. Cancer & Metabolism, 11, 7.
+ Open protocol
+ Expand
2

Cisplatin Resistance in NSCLC Cells

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Two pairs of parental vs. cisplatin resistant human NSCLC cells (A vs. ALC and FA vs. FC) and a pair of mouse Lewis lung cells (LLC vs. LLC-CR) were used. Cell line “A” was established with pleural fluid from a patient with adenocarcinoma. FA was established from a poorly differentiated squamous cell carcinoma. Cellular characteristics have been previously characterized (22 (link)–25 (link)) and routinely tested for mycoplasma infection (MycoAlert; Lonza cat#LT07–710). These cell lines were not derived from the patients reported here in this study. LLC and LL24 were purchased (ATCC). We established their cisplatin resistant variants using previously published methods (23 (link), 24 (link)). Note: ALC and FC exhibit 7 fold resistance to cisplatin. LLC-CR exhibits 3 fold resistance. LL24 is normal lung fibroblast. Supplementary Table1 shows the ID50 values for the sensitive and resistant cell lines. Recombinant human IFNγ was purchased from Biolegend (cat#570204). IDO1 inhibitors (Epacadostat (cat#T3545), PF-06840003 (cat#T4307), NLG-919 (cat#T1806), and Indoximod (cat# T6543)) were purchased from TargetMol. Dimethoxyflavone (DMF; cat#D6571), CH-223191 (cat#C8124), TIRON (4,5-dihydroxy-1,3-benzenedisulfonic; cat#172553), and NAD+ were purchased from Sigma.
Nguyen D.J., Theodoropoulos G., Li Y.Y., Wu C., sha W., Feun L.G., Lampidis T.J., Savaraj N, & Wangpaichitr M. (2019). Targeting the kynurenine pathway for the treatment of cisplatin resistant lung cancer. Molecular cancer research : MCR, 18(1), 105-117.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!